Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Marginal Zone Lymphoma Is Associated with Dysregulated Peripheral Blood Immunity Which Is Not Changed By Ibrutinib-Venetoclax Treatment

Joanne Elizabeth Davis, Lina HH Le, Mandy Ludford-Menting, Nicholas Holzwart, Sasanka M Handunnetti, Constantine S. Tam, Mary Ann Anderson, David S. Ritchie, Rachel Koldej

Blood (2024) 144 (Supplement 1): 4384.

https://doi.org/10.1182/blood-2024-199866

Published: 2024

Journal Articles

Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in NPM1 mutated or KMT2A- rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform Trial

Blood (2024) 144 (Supplement 1): 223.

https://doi.org/10.1182/blood-2024-202895

Published: 2024

Journal Articles

A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax +/- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial

Blood (2024) 144 (Supplement 1): 217.

https://doi.org/10.1182/blood-2024-199882

Published: 2024

Journal Articles

Real-World Patterns of Care and Outcomes for Non-Favourable Risk Acute Myeloid Leukemia Treated with Intensive Chemotherapy across Australia and New Zealand- Data Linkage between the ALLG National Blood Cancer Registry (NBCR) and the Australia and New Zealand Transplant and Cellular Therapy (ANZTCT) Registry

Blood (2024) 144 (Supplement 1): 3799.

https://doi.org/10.1182/blood-2024-209389

Published: 2024

Journal Articles

Evaluating a Multidisciplinary Model of Care for Inherited Bone Marrow Failure and Predisposition to Hematological Malignancy

Lucy C Fox, Nicole Den Elzen, Erin Goode, Kelsey Man, Lin Cheng, Stephanie Best, Jillian Francis, Laura Barth, Paul James, Karin A Thursky, Ashish Bajel, David S. Ritchie, Piers Blombery

Blood (2024) 144 (Supplement 1): 5015.

https://doi.org/10.1182/blood-2024-202704

Published: 2024

Journal Articles

T Cell CD62L Expression Following Nivolumab Therapy Is Associated with Long Term Response to Rituximab-Nivolumab in Treatment Naïve Follicular Lymphoma: Results from the 1 st FLOR Study

Rachel Koldej, Allison Barraclough, Sze Ting Lee, Huw Morgan, Nicholas Holzwart, Minu Koshy, Charmaine Smith, Geoffrey Chong, Michael Gilbertson, Colm Keane, Denise Lee, Leonid Churilov, David S. Ritchie, Eliza A. Hawkes

Blood (2024) 144 (Supplement 1): 4376.

https://doi.org/10.1182/blood-2024-199854

Published: 2024

Journal Articles

Rural/Regional Place of Residence Impacts Post Allogeneic Bone Marrow Transplant Overall Survival of Australian Patients with Acute Myeloid Leukaemia: An Anztct Registry Study

Blood (2024) 144 (Supplement 1): 7923.

https://doi.org/10.1182/blood-2024-204669

Published: 2024

Journal Articles

Prior Azacitidine and Ongoing Transfusion Dependence in MDS Patients Are Associated with Inferior Survival after Allogeneic Stem Cell Transplant

Miles Horton, Becky Leung, Ricky Nelles, Matthew Rubic, Christopher McKinnely, Alia Cibich, Mark R Dowling, Stewart Hunt, Lynette C.Y. Chee, Ashleigh P Scott, David S. Ritchie, Devendra Hiwase, Duncan Purtill, Abir Bhattacharya, Glen A Kennedy, Ashish Bajel

Blood (2024) 144 (Supplement 1): 7440.

https://doi.org/10.1182/blood-2024-209705

Published: 2024

Journal Articles

A Phase 1 Dose Escalation and Expansion Trial of Third-Generation CD19-Directed CAR T-Cells Incorporating CD28 and Toll-like Receptor 2 (TLR2) Co-Stimulation for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (ENABLE-1)

Blood (2024) 144 (Supplement 1): 2067.

https://doi.org/10.1182/blood-2024-201138

Published: 2024

Journal Articles

The brain may devise laws for the blood

David S. Ritchie

Blood (2024) 143 (10): 841–842.

https://doi.org/10.1182/blood.2023023291

Published: 2024

Journal Articles

Sensitive Molecular Detection of JAK2 V617F Is a Predictive Marker of Relapse in Patients with Myelofibrosis after Allogeneic Stem Cell Transplantation

Rithin Nedumannil, Tal Karmi, Piers Blombery, Charlotte Hughes, Jeff Szer, David S. Ritchie, Lynette C.Y. Chee

Blood (2023) 142 (Supplement 1): 629.

https://doi.org/10.1182/blood-2023-174666

Published: 2023

Journal Articles

A Phase 1 Dose Escalation Trial of Third-Generation CD19-Directed CAR T-Cells Incorporating CD28 and Toll-like Receptor 2 (TLR2) Intracellular Domains for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (ENABLE)

Robert Weinkove, Philip George, Robert Fyfe, Nathaniel Dasyam, Yasmin Nouri, Tess Ostapowicz, Stefan Mullins, Brigitta Mester, Giulia Giunti, Catherine M. Bollard, Travis Perera, Hayden Jina, Alwyn D'Souza, Le Qin, David S. Ritchie, Chris M.A. Frampton, Rachel Perret, Peng Li, Ian Hermans

Blood (2023) 142 (Supplement 1): 890.

https://doi.org/10.1182/blood-2023-178872

Published: 2023

Journal Articles

Lower Cumulative Incidence of Relapse but Higher Incidence of NRM in Patients with Poor Graft Function Following Allogeneic Stem Cell Transplantation

Ashvind Prabahran, Rachel Koldej, Lynette C.Y. Chee, David S. Ritchie

Blood (2023) 142 (Supplement 1): 4912.

https://doi.org/10.1182/blood-2023-190941

Published: 2023

Journal Articles

Evaluating Multidisciplinary Bone Marrow Failure Care (EMBRACE) - a Hybrid Implementation-Effectiveness Study

Lucy C. Fox, Nicole Den Elzen, Laura Barth, Kelsey Man, Paul James, Jillian Francis, Lin Cheng, Karin A Thursky, Ashish Bajel, David S. Ritchie, Piers Blombery

Blood (2023) 142 (Supplement 1): 369.

https://doi.org/10.1182/blood-2023-177593

Published: 2023

Journal Articles

Favorable Patient Survival after Failure of Venetoclax (ABT-199/ GDC-0199) Therapy for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Constantine Tam, MBBS, MD, Mary Ann Anderson, MBBS, David S. Ritchie, MDPhD, E. Henry Januszewicz, MBBS, Dennis Carney, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD

Blood (2015) 126 (23): 2939.

https://doi.org/10.1182/blood.V126.23.2939.2939

Published: 2015

Journal Articles

CAR-T Cells Are Serial Killers of Tumor Cells

Misty Jenkins, PhD, Alex Davenport, Ryan Cross, Carmen Yong, David S. Ritchie, MDPhD, Joe Trapani, Michael Kershaw, Phil Darcy, Paul Neeson, PhD

Blood (2015) 126 (23): 3088.

https://doi.org/10.1182/blood.V126.23.3088.3088

Published: 2015

Journal Articles

The Frequency of Cytomegalovirus (CMV)-Specific CD8+ T Cells Distinguishes CMV Clinical Outcomes Following Hematopoietic Allogeneic Stem Cell Transplant: A Prospective Multicentre Cohort Study

Michelle K Yong, Monica Slavin, David S. Ritchie, MDPhD, Andrew Spencer, Paul U Cameron, Orla Morrissey, Allen Cheng, Assia Samri, Guislaine Carcelain, Brigitte Autran, Sharon R Lewin

Blood (2015) 126 (23): 4312.

https://doi.org/10.1182/blood.V126.23.4312.4312

Published: 2015

Journal Articles

Targeting Mechanisms for Natural Killer Cell Dysfunction in Patients with Multiple Myeloma

Misty Jenkins, PhD, Rachael Canfield, BSc, Michael Robbins, BS, David S. Ritchie, MDPhD, Joe Trapani, Paul Neeson, BSc, PhD

Blood (2015) 126 (23): 4237.

https://doi.org/10.1182/blood.V126.23.4237.4237

Published: 2015

Journal Articles

The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial

Constantine Tam, MBBS, MD, Andrew P Grigg, MBBS MD, Stephen Opat, MBBS, Matthew Ku, MBBS, Michael Gilbertson, MBBS, Mary Ann Anderson, MBBS, John F. Seymour, MBBS, PhD, David S. Ritchie, MDPhD, Carmen Dicorleto, Belinda Dimovski, Eric Hedrick, Jianxin Yang, Lai Wang, PhD, Lusong Luo, Ling Xue, Andrew W. Roberts, MBBS, PhD

Blood (2015) 126 (23): 832.

https://doi.org/10.1182/blood.V126.23.832.832

Published: 2015

Journal Articles

Prognostic Markers in Core-Binding Factor Acute Myeloid Leukaemia

Ashvind A Prabahran, MBBS, Mark Tacey, BSc, Shaun Fleming, MBBS (Hons), FRACP, FRCPA, Danielle Strong, Andrew Wei, MBBS, PhD, Courtney Tate, MBBS, Paula Marlton, MBBS, Joel Wight, MBBS, Andrew Grigg, MBBS, MD FRACP, FRACPA, Annabel Tuckfield, MBBS, FRACP, FRCPA, PhD, Jeff Szer, MB, BS, FRACP, David S. Ritchie, MDPhD, Lynette C.Y. Chee, MBBS, FRACP, FRCPA, PhD

Blood (2015) 126 (23): 2599.

https://doi.org/10.1182/blood.V126.23.2599.2599

Published: 2015

NARROW

Marginal Zone Lymphoma Is Associated with Dysregulated Peripheral Blood Immunity Which Is Not Changed By Ibrutinib-Venetoclax Treatment

Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in NPM1 mutated or KMT2A- rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform Trial

A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax +/- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial

Evaluating a Multidisciplinary Model of Care for Inherited Bone Marrow Failure and Predisposition to Hematological Malignancy

T Cell CD62L Expression Following Nivolumab Therapy Is Associated with Long Term Response to Rituximab-Nivolumab in Treatment Naïve Follicular Lymphoma: Results from the 1 st FLOR Study

Rural/Regional Place of Residence Impacts Post Allogeneic Bone Marrow Transplant Overall Survival of Australian Patients with Acute Myeloid Leukaemia: An Anztct Registry Study

Prior Azacitidine and Ongoing Transfusion Dependence in MDS Patients Are Associated with Inferior Survival after Allogeneic Stem Cell Transplant

A Phase 1 Dose Escalation and Expansion Trial of Third-Generation CD19-Directed CAR T-Cells Incorporating CD28 and Toll-like Receptor 2 (TLR2) Co-Stimulation for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (ENABLE-1)

The brain may devise laws for the blood

Sensitive Molecular Detection of JAK2 V617F Is a Predictive Marker of Relapse in Patients with Myelofibrosis after Allogeneic Stem Cell Transplantation

A Phase 1 Dose Escalation Trial of Third-Generation CD19-Directed CAR T-Cells Incorporating CD28 and Toll-like Receptor 2 (TLR2) Intracellular Domains for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (ENABLE)

Lower Cumulative Incidence of Relapse but Higher Incidence of NRM in Patients with Poor Graft Function Following Allogeneic Stem Cell Transplantation

Evaluating Multidisciplinary Bone Marrow Failure Care (EMBRACE) - a Hybrid Implementation-Effectiveness Study

Favorable Patient Survival after Failure of Venetoclax (ABT-199/ GDC-0199) Therapy for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

CAR-T Cells Are Serial Killers of Tumor Cells

The Frequency of Cytomegalovirus (CMV)-Specific CD8+ T Cells Distinguishes CMV Clinical Outcomes Following Hematopoietic Allogeneic Stem Cell Transplant: A Prospective Multicentre Cohort Study

Targeting Mechanisms for Natural Killer Cell Dysfunction in Patients with Multiple Myeloma

The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial

Prognostic Markers in Core-Binding Factor Acute Myeloid Leukaemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only